• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form POS EX filed by Abpro Holdings Inc

    4/23/25 4:16:11 PM ET
    $ABP
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ABP alert in real time by email
    POS EX 1 ea0238814-posex_abprohold.htm POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-1

    As filed with the Securities and Exchange Commission on April 23, 2025

    Registration No. 333-284021

     

     

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

     

    POST-EFFECTIVE AMENDMENT NO. 1

    TO

    FORM S-1

    REGISTRATION STATEMENT

    Under

    The Securities Act of 1933

     

     

     

    Abpro Holdings, Inc.

    (Exact name of Registrant as specified in its charter)

     

     

     

    Delaware   2834   87-1013956

    (State or other jurisdiction of

    incorporation or organization)

     

    (Primary Standard Industrial

    Classification Code Number)

     

    (I.R.S. Employer

    Identification No.)

     

    68 Cummings Park Drive

    Woburn, Massachusetts 01801

    1-800 -396-5890

    (Address, including zip code, and telephone number, including area code, of registrant’s principal executive offices)

     

    Miles Suk

    Chief Executive Officer

    Abpro Holdings, Inc.

    68 Cummings Park Drive

    Woburn, Massachusetts 01801

    1-800 -396-5890

    (Name, address, including zip code, and telephone number, including area code, of agent for service)

     

     

     

    Copies to:

    Jonathan H. Talcott

    E. Peter Strand

    Michael K. Bradshaw, Jr.

    Nelson Mullins Riley & Scarborough LLP

    101 Constitution Avenue, NW, Suite 900

    Washington, D.C. 20001

    (202) 689-2800

     

     

     

    Approximate date of commencement of proposed sale to the public: From time to time after this Registration Statement becomes effective.

     

    If any of the securities being registered on this Form are to be offered on a delayed or continuous basis pursuant to Rule 415 under the Securities Act of 1933 check the following box: ☒

     

    If this form is filed to register additional securities for an offering pursuant to Rule 462(b) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering.  ☐

     

    If this form is a post-effective amendment filed pursuant to Rule 462(c) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering.  ☐

     

    If this form is a post-effective amendment filed pursuant to Rule 462(d) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering.  ☒ (333-284021)

     

    Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

     

    Large accelerated filer ☐ Accelerated filer ☐
    Non-accelerated filer ☒ Smaller reporting company ☒
        Emerging growth company ☒

     

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act.  ☐

     

     

     

     

    This Post-Effective Amendment No. 1 to the Registration Statement shall become effective upon filing with the Securities and Exchange Commission in accordance with Rule 462(d) under the Securities Act of 1933, as amended.

     

     

     

     

     

     

    EXPLANATORY NOTE

     

    This Post-Effective Amendment No. 1 (this “Amendment”) to the Registration Statement on Form S-1 of Abpro Holdings, Inc. (File No. 333-284021), initially filed on December 23, 2024, and declared effective by the SEC on February 12, 2025 (the “Registration Statement”), is being filed as an exhibit-only filing solely to file a consent of Wolf & Company, P.C. with respect to its report dated April 15, 2025, related to the financial statements of Abpro Holdings, Inc. contained in the Annual Report on Form 10-K of Abpro Holdings, Inc. for the year ended December 31, 2024 and included in the Prospectus Supplement No. 1 dated April 23, 2025 filed pursuant to Rule 424(b)(3), filed herewith as Exhibit 23.1 (the “Consent”). Accordingly, this Amendment consists only of the facing page, this explanatory note, Item 16 of Part II of the Registration Statement, the signature pages to the Registration Statement, and the Consent. The prospectus and the balance of Part II of the Registration Statement are unchanged hereby and have been omitted.

     

     

     

     

    PART II — INFORMATION NOT REQUIRED IN PROSPECTUS

     

    Item 16. Exhibits and Financial Statement Schedules.

     

    Exhibit

    Number

      Description
    23.1*   Consent of Wolf & Company, P.C.

     

    *Filed herewith.

     

    II-1

     

     

    SIGNATURES

     

    Pursuant to the requirements of the Securities Act of 1933, as amended, the registrant has duly caused this Post-Effective Amendment No. 1 to the Registration Statement on Form S-1 to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Woburn, Massachusetts, on the 23rd day of April 2025.

     

      ABPRO HOLDINGS, INC.
         
      By: /s/ Miles Suk
        Miles Suk
        Chief Executive Officer and Chairman of the Board

     

    POWER OF ATTORNEY

     

    Each person whose signature appears below hereby constitutes and appoints Miles Suk, the individual’s true and lawful attorney-in-fact and agent, with full power of substitution and resubstitution, for the person and in his or her name, place and stead, in any and all capacities, to sign this Registration Statement and any or all amendments, including post-effective amendments to the Registration Statement, including a prospectus or an amended prospectus therein and any Registration Statement for the same offering that is to be effective upon filing pursuant to Rule 462 under the Securities Act, and all other documents in connection therewith to be filed with the Securities and Exchange Commission, granting unto said attorneys-in-fact and agents, and each of them, full power and authority to do and perform each and every act and thing requisite and necessary to be done in and about the premises, as fully to all intents and purposes as he or she might or could do in person, hereby ratifying and confirming all that said attorneys-in-fact as agents or any of them, or their substitute or substitutes, may lawfully do or cause to be done by virtue hereof.

     

    Pursuant to the requirements of the Securities Act of 1933, as amended, this Post-Effective Amendment No. 1 to the Registration Statement on Form S-1 has been signed below by the following persons in the capacities and on the dates indicated.

     

    Name   Position   Date
             
    /s/ Miles Suk   Chief Executive Officer and Chairman of the Board   April 23, 2025
    Miles Suk (Principal Executive Officer, Principal Financial and Accounting Officer)  
             
    /s/ Anthony D. Eisenberg   Director   April 23, 2025
    Anthony D. Eisenberg    
             
    /s/ Soo Young Lee   Director   April 23, 2025
    Soo Young Lee    
             
    /s/ Ian McDonald   Director   April 23, 2025
    Ian McDonald    

     

     

    II-2

     

     

    Get the next $ABP alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $ABP

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $ABP
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • CEO and Chairman Suk Jin Wook (Miles) bought $4,212 worth of shares (16,200 units at $0.26), increasing direct ownership by 12% to 146,477 units (SEC Form 4)

      4 - Abpro Holdings, Inc. (0001893219) (Issuer)

      5/19/25 8:37:52 PM ET
      $ABP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • CEO and Chairman Suk Jin Wook (Miles) bought $1,081 worth of shares (4,325 units at $0.25), increasing direct ownership by 3% to 130,277 units (SEC Form 4)

      4 - Abpro Holdings, Inc. (0001893219) (Issuer)

      5/1/25 4:21:30 PM ET
      $ABP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • CEO and Chairman Suk Jin Wook (Miles) bought $11,113 worth of shares (34,002 units at $0.33), increasing direct ownership by 37% to 125,902 units (SEC Form 4)

      4 - Abpro Holdings, Inc. (0001893219) (Issuer)

      4/25/25 4:58:51 PM ET
      $ABP
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ABP
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • CEO and Chairman Suk Jin Wook (Miles) bought $4,212 worth of shares (16,200 units at $0.26), increasing direct ownership by 12% to 146,477 units (SEC Form 4)

      4 - Abpro Holdings, Inc. (0001893219) (Issuer)

      5/19/25 8:37:52 PM ET
      $ABP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • CEO and Chairman Suk Jin Wook (Miles) bought $1,081 worth of shares (4,325 units at $0.25), increasing direct ownership by 3% to 130,277 units (SEC Form 4)

      4 - Abpro Holdings, Inc. (0001893219) (Issuer)

      5/1/25 4:21:30 PM ET
      $ABP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • CEO and Chairman Suk Jin Wook (Miles) bought $11,113 worth of shares (34,002 units at $0.33), increasing direct ownership by 37% to 125,902 units (SEC Form 4)

      4 - Abpro Holdings, Inc. (0001893219) (Issuer)

      4/25/25 4:58:51 PM ET
      $ABP
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ABP
    SEC Filings

    See more
    • SEC Form 424B3 filed by Abpro Holdings Inc

      424B3 - Abpro Holdings, Inc. (0001893219) (Filer)

      5/15/25 5:25:47 PM ET
      $ABP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 10-Q filed by Abpro Holdings Inc

      10-Q - Abpro Holdings, Inc. (0001893219) (Filer)

      5/15/25 4:49:25 PM ET
      $ABP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form EFFECT filed by Abpro Holdings Inc

      EFFECT - Abpro Holdings, Inc. (0001893219) (Filer)

      5/6/25 12:15:38 AM ET
      $ABP
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ABP
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Abpro and Celltrion Unveil Preclinical Data for ABP-102/CT-P72 at AACR 2025, Showcasing Potential Best-in-Class HER2 x CD3 T-Cell Engager

      Data suggest potential for superior tumor selectivity, potent efficacy, and improved safety profileAbpro and Celltrion have a strategic partnership for worldwide development and commercialization of ABP-102/CT-P72HER2-positive cancers represent up to 30 percent of all cases of breast, gastric, pancreatic, colorectal and other forms of cancer WOBURN, Mass., April 27, 2025 (GLOBE NEWSWIRE) -- Abpro Holdings, Inc. (NASDAQ:ABP) ("Abpro"), a biotechnology company dedicated to advancing next-generation antibody therapies for severe and life-threatening diseases, and Celltrion, a leading biopharmaceutical company, today unveiled preclinical data for ABP-102/CT-P72 in an oral presentation at the

      4/27/25 2:00:00 PM ET
      $ABP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Abpro Announces Oral Presentation of First Preclinical Data for ABP-102/CT-P72, a Tetravalent Bispecific HER2 x CD3 T-Cell Engager, at AACR Annual Meeting 2025

      WOBURN, Mass., March 25, 2025 (GLOBE NEWSWIRE) -- Abpro Holdings, Inc. (NASDAQ:ABP) ("Abpro"), a biotechnology company dedicated to advancing next-generation antibody therapies for severe and life-threatening diseases, today announced an oral presentation of preclinical data for ABP-102/CT-P72 at the American Association for Cancer ResearchⓇ Annual Meeting 2025 ("AACR 2025") in the New Drugs on the Horizon session. AACR 2025 is taking place April 25-30, at the McCormick Place Convention Center in Chicago. Invited speaker presentation details Title:ABP-102/CT-P72: a novel HER2 x CD3 T cell engager with selective activity for HER2-overexpressing tumors and reduced activity on cells with

      3/25/25 4:30:18 PM ET
      $ABP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Abpro Statement on the Departure of Former CEO Ian Chan

      WOBURN, Mass., March 10, 2025 (GLOBE NEWSWIRE) -- Abpro Holdings, Inc. (NASDAQ:ABP) ("Abpro"), a biotechnology company dedicated to advancing next-generation antibody therapies for severe and life-threatening diseases announced today the departure of Chief Executive Officer Ian Chan. Commenting on the leadership change, Abpro Board Chairman and CEO Miles Suk, said, "As disclosed in our regulatory filing on Friday, the Board has decided to part ways with Ian Chan. I want to thank Ian for his service and wish him well. This leadership transition, however, does not affect our stability or direction. Instead, it marks the first step toward a stronger, more promising future. We remain fully co

      3/10/25 6:34:55 PM ET
      $ABP
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ABP
    Leadership Updates

    Live Leadership Updates

    See more
    • Abpro Statement on the Departure of Former CEO Ian Chan

      WOBURN, Mass., March 10, 2025 (GLOBE NEWSWIRE) -- Abpro Holdings, Inc. (NASDAQ:ABP) ("Abpro"), a biotechnology company dedicated to advancing next-generation antibody therapies for severe and life-threatening diseases announced today the departure of Chief Executive Officer Ian Chan. Commenting on the leadership change, Abpro Board Chairman and CEO Miles Suk, said, "As disclosed in our regulatory filing on Friday, the Board has decided to part ways with Ian Chan. I want to thank Ian for his service and wish him well. This leadership transition, however, does not affect our stability or direction. Instead, it marks the first step toward a stronger, more promising future. We remain fully co

      3/10/25 6:34:55 PM ET
      $ABP
      Biotechnology: Pharmaceutical Preparations
      Health Care